The shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting at 15:00 pm. on Thursday, December 3, 2026.
Type 1 diabetes is a chronic progressive autoimmune disease where the immune system attacks and breaks down the insulin-producing cells in the pancreas. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 %.
Retogatein (rhGAD65/alum) is an investigational antigen-specific immunotherapy for the prevention and treatment of type 1 diabetes. Retogatein is under development for individuals with type 1 diabetes carrying the genetic HLA DR3-DQ2 haplotype.